Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Non Operating Income (2016 - 2025)

Viking Therapeutics' Non Operating Income history spans 12 years, with the latest figure at $7.1 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 34.61% year-over-year to $7.1 million; the TTM value through Dec 2025 reached $33.7 million, down 17.71%, while the annual FY2025 figure was $33.7 million, 17.71% down from the prior year.
  • Non Operating Income for Q4 2025 was $7.1 million at Viking Therapeutics, down from $7.8 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $11.8 million in Q2 2024 and bottomed at $142000.0 in Q1 2022.
  • The 5-year median for Non Operating Income is $4.6 million (2023), against an average of $4.6 million.
  • The largest annual shift saw Non Operating Income plummeted 84.41% in 2021 before it soared 2168.84% in 2023.
  • A 5-year view of Non Operating Income shows it stood at $153000.0 in 2021, then skyrocketed by 373.2% to $724000.0 in 2022, then soared by 546.41% to $4.7 million in 2023, then skyrocketed by 131.22% to $10.8 million in 2024, then crashed by 34.61% to $7.1 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Non Operating Income are $7.1 million (Q4 2025), $7.8 million (Q3 2025), and $9.0 million (Q2 2025).